Genetic-targeted therapy of thyroid cancer: a real promise.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. B-Raf mutation and papillary thyroid carcinoma patients.Oncology letters · 2016
   Article
2. Molecular pathogenesis and mechanisms of thyroid cancer.Nature reviews. Cancer · 2013
   Review
3. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.The Journal of clinical endocrinology and metabolism · 2012
   Article
4. Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets.Frontiers in endocrinology · 2012
   Article
5. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.The Journal of clinical endocrinology and metabolism · 2011
   Article
6. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).Biochemical and biophysical research communications · 2011
   Article
7. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.Thyroid : official journal of the American Thyroid Association · 2010
   Review
8. Current concepts and future directions in differentiated thyroid cancer.The Clinical biochemist. Reviews · 2010
   Article
9. Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit.The Journal of clinical endocrinology and metabolism · 2009
   Article

Corrections and comments

• Comment on
  Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.2009

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as